| scholarly article | Q13442814 |
| P2093 | author name string | Li Wang | |
| Na Liu | |||
| Shougang Zhuang | |||
| Liuqing Xu | |||
| Yingfeng Shi | |||
| Andong Qiu | |||
| Haiping Mao | |||
| Xiujuan Zang | |||
| Chongxiang Xiong | |||
| P2860 | cites work | Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities | Q27027433 |
| HB-EGF is produced in the peritoneal cavity and enhances mesothelial cell adhesion and migration. | Q31904044 | ||
| Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma | Q33863710 | ||
| High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR | Q34075493 | ||
| Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway | Q34763969 | ||
| Thalidomide prevents the progression of peritoneal fibrosis in mice | Q34985928 | ||
| Blocking TGF-β1 protects the peritoneal membrane from dialysate-induced damage | Q35210203 | ||
| NF-κB and STAT3 - key players in liver inflammation and cancer | Q35347976 | ||
| EGFR signal transactivation in cancer cells | Q35594162 | ||
| EGFR signaling promotes TGFβ-dependent renal fibrosis | Q35715849 | ||
| Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. | Q35917468 | ||
| Role of epidermal growth factor receptor in acute and chronic kidney injury | Q36224457 | ||
| ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors | Q36504484 | ||
| Epithelial-to-mesenchymal transition of the mesothelial cell--its role in the response of the peritoneum to dialysis | Q36529429 | ||
| Mediators of inflammation and fibrosis | Q36843507 | ||
| Peritoneal fibrosis intervention. | Q36843521 | ||
| Pathogenesis and treatment of peritoneal membrane failure | Q36949948 | ||
| Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury | Q36986519 | ||
| Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. | Q37632107 | ||
| EGF receptor activation by GPCRs: an universal pathway reveals different versions | Q37732563 | ||
| The myofibroblast matrix: implications for tissue repair and fibrosis. | Q37733670 | ||
| Determinants of peritoneal membrane function over time. | Q37857972 | ||
| Angiogenesis in peritoneal dialysis | Q37892307 | ||
| Mechanisms and interventions in peritoneal fibrosis | Q37936293 | ||
| Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions | Q38024974 | ||
| Advances in peritoneal dialysis: a review | Q38034577 | ||
| Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis. | Q38087161 | ||
| Epithelial growth factor receptor-activated nuclear factor κB signaling and its role in epithelial growth factor receptor-associated tumors | Q38165683 | ||
| Pharmacologic targets and peritoneal membrane remodeling | Q38187841 | ||
| NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links | Q38227386 | ||
| Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro | Q39176424 | ||
| A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy | Q39697103 | ||
| Morphological changes of the peritoneal membrane in patients with long-term dialysis | Q41695541 | ||
| Smad3-dependent and -independent pathways are involved in peritoneal membrane injury | Q43231611 | ||
| Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. | Q43680975 | ||
| Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis | Q44400750 | ||
| Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition | Q44807372 | ||
| Calcitriol decreases TGF-β1 and angiotensin II production and protects against chlorhexide digluconate-induced liver peritoneal fibrosis in rats | Q45012352 | ||
| TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model | Q45085906 | ||
| Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-kappaB in peritoneal mesothelial cells | Q46976341 | ||
| H2O2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells | Q47790130 | ||
| Epidermal growth factor modifies the expression and function of extracellular matrix adhesion receptors expressed by peritoneal mesothelial cells from patients on CAPD. | Q52535162 | ||
| Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. | Q52561638 | ||
| Morphologic changes in the peritoneal membrane of patients with renal disease | Q77531583 | ||
| Growth factors VEGF and TGF-beta1 in peritoneal dialysis | Q78115905 | ||
| Smad7 transgene attenuates peritoneal fibrosis in uremic rats treated with peritoneal dialysis | Q81251018 | ||
| Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction | Q81583826 | ||
| Suramin inhibits the development and progression of peritoneal fibrosis | Q85208809 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 9 | |
| P304 | page(s) | 2631-2644 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis | |
| P478 | volume | 27 |
| Q39179076 | Blocking fibrotic signaling in fibroblasts from patients with carpal tunnel syndrome. |
| Q92617632 | Dioscin ameliorates peritoneal fibrosis by inhibiting epithelial-to-mesenchymal transition of human peritoneal mesothelial cells via the TLR4/MyD88/NF-κB signaling pathway |
| Q93111087 | Effect of astragaloside IV and the role of nuclear receptor RXRα in human peritoneal mesothelial cells in high glucose‑based peritoneal dialysis fluids |
| Q91973321 | Expression of XBP1s in peritoneal mesothelial cells is critical for inflammation-induced peritoneal fibrosis |
| Q90451156 | Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis |
| Q46525336 | Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis |
| Q97529188 | Hypochlorite-induced porcine model of peritoneal fibrosis through the activation of IL1β-CX3CL1-TGFβ1 signal axis |
| Q33906324 | Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis |
| Q26768501 | Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis |
| Q50528626 | Pharmacological inhibition of heparin-binding EGF-like growth factor promotes peritoneal angiogenesis in a peritoneal dialysis rat model |
| Q47096709 | Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition |
Search more.